Turning Glucosuria into a therapy: Efficacy and safety with SGLT2 inhibitors

Current Diabetes Reports

Volumn 10, Issue 2, 2010, Pages 101-107

  Patel, Anupa K ^a   Fonseca, Vivian ^a  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

Glucose; Glucosuria; Hyperglycemia; SGLT2

Indexed keywords

3 (5 BENZOFURANYL) 1 [2 HYDROXY 6 [6 O (METHOXYCARBONYL) BETA DEXTRO GLUCOPYRANOSYL] 4 METHYLPHENYL] 1 PROPANONE; ANTIDIABETIC AGENT; ASP 1941; AVE 2268; BI 10773; BI 44847; CANAGLIFLOZIN; DAPAGLIFLOZIN; DSP 3235; INSULIN; ORAL ANTIDIABETIC AGENT; PHLORIZIN; R 7201; REMOGLIFLOZIN ETABONATE; SAR 474832; SAR 7226; SERGLIFLOZIN ETABONATE; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; TA 7284; TS 033; UNCLASSIFIED DRUG; YM 543;

CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; GLUCOSE HOMEOSTASIS; GLUCOSE TRANSPORT; GLUCOSURIA; HUMAN; HYPERGLYCEMIA; KIDNEY TUBULE ABSORPTION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; UROGENITAL TRACT INFECTION; VAGINA MYCOSIS; VULVOVAGINAL DISEASE; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); GLYCOSURIA; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; GLYCOSURIA; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; SODIUM-GLUCOSE TRANSPORTER 2; TREATMENT OUTCOME;

EID: 77953614344     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-010-0095-5     Document Type: Review

References (40)

1. Wagman A, Nuss JM: Current therapies and emerging targets for the treatment of diabetes. Curr Pharm Des 2001, 7:417-450.
2. Marsenic O: Glucose control by the kidney: an emerging target in diabetes. Am J Kidney Dis 2009, 53:875-883.
3. Wright EM, Turk E: The sodium/glucose cotransport family SCL5. Pflugers Arch 2004, 447:510-518.
4. Wright EM: Renal Na(+)-glucose cotransporters. Am J Physiol Renal Physiol 2001, 280:F10-F18.
5. Bakris GL, Fonseca V, Sharma K, Wright EM: Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int 2009, 75:1272-1277.
6. Wood IS, Trayburn P: Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. Br J Nutr 2003, 89:3-9.
7. Castaneda F, Burse A, Boland W, Kinne RK: Thioglycosides as inhibitors of hSGLT1 and hSGLT2: potential therapeutic agents for the control of hyperglycemia in diabetes. Int J Med Sci 2007, 4:131-139.
8. Rahmoune H, Thompson PW, Ward JM, et al.: Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 2005, 54:3427-3434.
9. Kanai Y, Lee WS, You G, et al.: The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 1994, 93:397-404.
10. Hediger MA, Rhoads DB: Molecular physiology of sodium- glucose cotransporters. Physiol Rev 1994, 74:993-1026.
11. Zhou L, Cryan EV, D'Andrea MR, et al.: Human cardiomyocytes express high level of Na+/glucose cotransporter 1 (SGLT1). J Cell Biochem 2003, 90:339-346.
12. Thomson AB, Wild G: Adaptation of intestinal nutrient transport in health and disease. Part I. Dig Dis Sci 1997, 42:453-469. (Pubitemid 27148329)
13. Freitas HS, Anhe GF, Melo KF, et al.: Na(+)-glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1alpha expression and activity. Endocrinology 2008, 149:717-724.
14. Arakawa K, Ishihara T, Oku A, et al.: Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095. Br J Pharmacol 2001, 132:578-586.
15. NCBI: OMIM-Online Mendelian Inheritance in Man. Available at http://www.ncbi.nlm.nih.gov/omim. Accessed December 2009.
16. Wright EM, Hirayama BA, Loo DF: Active sugar transport in health and disease. J Intern Med 2007, 261:32-43.
17. Santer R, Kinner M, Lassen CL, et al.: Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 2003, 14:2873-2882.
18. Jabbour SA, Goldstein BJ: Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. Int J Clin Pract 2008, 62:1279-1284.
19. Idris I, Donnelly R: Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug. Diabetes Obes Metab 2009, 11:79-88.
20. Ehrenkranz JR, Lewis NG, Kahn CR, Roth J: Phlorizin: a review. Diabetes Metab Res Rev 2005, 21:31-38.
21. Meng W, Ellsworth BA, Nirschl AA, et al.: Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2008, 51:1145-1149.
22. Katsuno K, Fujimori Y, Takemura Y, et al.: Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther 2007, 320:323-330.
23. Rossetti L, Smith D, Shulman GI, et al.: Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 1987, 79:1510-1515.
24. U.S. National Institutes of Health: Registry of ClinicalTrials.gov. Available at http://www.clinicaltrials.gov. Accessed December 2009.
25. Kipnes M: Dapagliflozin: an emerging treatment option in type 2 diabetes. Expert Opin Investig Drugs 2009, 18:327-334.
26. Fujimori Y, Katsuno K, Ojima K, et al.: Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats. Eur J Pharmacol 2009, 609:148-154.
27. Ghosh S, Shen Y, Harrington WW, et al.: Metabolic responses to a sodium-glucose transporter-2 inhibitor, GW869682, assessed by whole-genome transcript profiling. Diabetologia 2007, 50 (Suppl 1):S376.
28. DiabesityDigest.com, your online resource for obesity and type 2 diabetes. Available at http://www.diabesitydigest.com. Accessed December 2009.
29. Fujimori Y, Katsuno K, Nakashima I, et al.: Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 2008, 327:268-276.
30. Kissei Pharmaceutical Co., Ltd. Available at http://www.kissei.co. jp. Accessed November 2009.
31. Wancewicz EV, Siwkowski A, Meibohm B, et al.: Long-term safety and efficacy of ISIS 388626, an optimized SGLT2 antisense inhibitor, in multiple diabetic and euglycemic species. Presented at the 68th Scientific Sessions of the American Diabetes Association. San Francisco, CA; June 6-10, 2008.
32. Bhanot S, Murray SF, Booten SL, et al.: ISIS 388626, an SGLT2 Antisense drug, causes robust and sustained glucosuria in multiple species and is safe and well tolerated. Presented at the 69th Scientific Sessions of the American Diabetes Association. New Orleans, LA; June 5-9, 2009.
33. Komoroski B, Vachharajani N, Feng Y, et al.: Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2009, 85:513-519.
34. List JF, Woo V, Morales E, et al.: Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009, 32:650-657.
35. Oku A, Ueta K, Arakawa K, et al.: T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 1999, 48:1794-1800.
36. Tsujihara K, Hongu M, Saito K, et. al.: Na(+)-glucose cotransporter (SGLT) inhibitors as antidiabetic agents. 4. Synthesis and pharmacological properties of 4'-dehydroxyphlorizin derivatives substituted on the B ring. J Med Chem 1999, 42:5311-5324.
37. Adachi T, Yasuda K, Okamoto Y, et al.: T-1095, a renal Na+-glucose transporter inhibitor, improves hyperglycemia in streptozotocin-induced diabetic rats. Metabolism 2000, 49:990-995.
38. Ueta K, Ishihara T, Matsumoto Y, et al.: Long-term treatment with the Na+-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki Rats. Life Sci 2005, 76:2655-2668.
39. Wilding JP, Norwood P, T'Joen C, et al.: A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 2009, 32:1656-1662.
40. Geerlings SE, Stolk RP, Camps MJ, et al.: Risk factors for symptomatic urinary tract infection in women with diabetes. Diabetes Care 2000, 23:1737-1741.